|Bid||8.80 x 800|
|Ask||9.80 x 900|
|Day's Range||9.32 - 9.80|
|52 Week Range||8.65 - 18.95|
|Beta (3Y Monthly)||2.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Jim Cramer chats with Alder Biopharmaceuticals CEO Robert Azelby to find out what the company is doing to address chronic migraine.
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.
Leading up to the anticipated February 2020 FDA approval date, Alder plans to double the size of its workforce.
Alder BioPharmaceuticals (ALDR) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
Alder Biopharmaceuticals Inc NASDAQ NMS:ALDRView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for ALDR with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding ALDR is favorable, with net inflows of $2.42 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
With the fourth-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Alder Biopharmaceuticals Inc (NASDAQ:ALDR). Alder Biopharmaceuticals Inc (NASDAQ:ALDR) was in […]
Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.
In a significant milestone for Alder, the U.S. Food and Drug Administration agreed on April 22 to review the biologics license application for the company’s flagship migraine drug, the company discovered and developed over the last decade. FDA approval could come as early as the first quarter of 2020.
The Bothell, Washington-based company said it had a loss of $1.63 per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.
Alder Biopharmaceuticals could be an acquisition target, an analyst said Tuesday after the Food and Drug Administration accepted its application for a migraine-prevention treatment.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) Moleculin Biotech Inc (NASDAQ: MBRX ) (announcement ...
An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.